FrancophonIA/ELRC3.0 huggingface dataset:
English: The CHMP concluded that, in accordance with EU requirements, Pioglitazone ratio had been shown to have comparable quality and to be bioequivalent to Actos.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Pioglitazone ratio primerljivo raven kakovosti kot zdravilo Actos ter da mu je biološko enakovredno.
English: Pioglitazone ratio was to be used on its own in patients for whom metformin (another antidiabetes medicine) is not suitable.
Slovenian: Prav tako naj bi se uporabljalo samostojno pri bolnikih, za katere metformin (drugo zdravilo proti sladkorni bolezni) ni primeren.
English: Pioglitazone ratio was also to be used together with insulin in patients who are not satisfactorily controlled with insulin alone and cannot take metformin.
Slovenian: Uporabljalo naj bi se tudi skupaj z insulinom pri bolnikih, pri katerih bolezen ni zadostno nadzorovana z insulinom samim in za katere metformin ni primeren.
English: What is Pioglitazone ratio?
Slovenian: Kaj je zdravilo Pioglitazone ratio?
English: How is Pioglitazone ratio expected to work?
Slovenian: Kako naj bi zdravilo Pioglitazone ratio delovalo?
English: What was Pioglitazone ratio expected to be used for?
Slovenian: Za kaj naj bi se zdravilo Pioglitazone ratio uporabljalo?
English: The active substance in
Slovenian: Zdravilna
English: The European Commission granted a marketing authorisation valid throughout the European Union for Zyclara on 23 August 2012.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Zyclara, veljavno po vsej Evropski uniji, izdala 23. avgusta 2012.
English: What measures are being taken to ensure the safe and effective use of Zyclara?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Zyclara?
English: Zyclara imiquimod
Slovenian: Zyclara imikvimod
English: The full EPAR for Zyclara can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Zyclara je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: In addition, its lower strength allows it to be used across larger areas of the skin and thereby treat more of the affected skin.
Slovenian: Poleg tega njegova manjša jakost omogoča, da se uporablja na večjih predelih kože, kar omogoča zdravljenje večjih površin prizadete kože.
English: Some other side effects, including headache and tiredness, were also reported.
Slovenian: Poročali so tudi o nekaj drugih neželenih učinkih, vključno z glavobolom in utrujenostjo.
English: This means that it is similar to a ‘reference medicine' containing the same active substance, but Zyclara is available in a different strength.
Slovenian: To pomeni, da je podobno referenčnemu zdravilu, ki vsebuje enako zdravilno učinkovino, vendar je zdravilo Zyclara na voljo z drugačno jakostjo.
English: If actinic keratosis does not improve enough with Zyclara, a different treatment should be tried.
Slovenian: Če se aktinična keratoza z zdravilom Zyclara ne izboljša dovolj, je treba poskusiti z drugačnim zdravljenjem.
English: Other information about Zyclara
Slovenian: Druge informacije o zdravilu Zyclara
English: What benefits of Zyclara have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Zyclara izkazalo v študijah?
English: When imiquimod is applied to the skin, it acts locally on the immune system to trigger the release of cytokines, including interferon.
Slovenian: Ko se imikvimod nanese na kožo, deluje lokalno na imunski sistem, da spodbudi sproščanje citokinov, vključno z interferonom.
English: This is followed by a 2-week break without treatment and then a further 2 weeks of treatment.
Slovenian: Temu sledita dva tedna premora brez zdravljenja in nato dodatno dvotedensko zdravljenje.
English: This is a summary of the European public assessment report (EPAR) for Zyclara.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Zyclara.
English: Zyclara is a ‘hybrid medicine'.
Slovenian: Zdravilo Zyclara je „hibridno zdravilo“.
English: What is Zyclara and what is it used for?
Slovenian: Kaj je zdravilo Zyclara in za kaj se uporablja?
English: The European Medicines Agency concluded that Zyclara 3.75% cream has been shown to be effective at clearing actinic keratosis from the skin and that its use did not raise significant safety concerns.
Slovenian: Evropska agencija za zdravila je zaključila, da se je zdravilo Zyclara 3,75 % krema izkazala za učinkovito pri odstranjevanju aktiničnih keratoz s kože in da njena uporaba ni sprožila večjih pomislekov glede varnosti.
English: Actinic keratosis is a precancerous, abnormal skin growth that develops after too much exposure to sunlight.
Slovenian: Aktinična keratoza je predrakava, nenormalna kožna tvorba, ki se razvije ob preveliki izpostavljenosti sončni svetlobi.
English: If actinic keratosis is cleared after two 2-week courses but then it comes back, it can be treated again with one or two 2-week treatment courses provided these are given after a break of at least 12 weeks from the original treatment.
Slovenian: Če aktinična keratoza izgine po dveh dvotedenskih zdravljenjih, nato pa se znova pojavi, se lahko dvotedensko zdravljenje ponovi enkrat ali dvakrat, če je od prvotnega zdravljenja minilo vsaj 12 tednov.
English: The Agency therefore decided that Zyclara's benefits are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: Agencija je zato zaključila, da so koristi zdravila Zyclara večje od z njim povezanih tveganj, in priporočila, da se zanj izda dovoljenje za promet.
English: Zyclara has been shown to be effective in clearing actinic keratosis from the skin in two main studies involving 479 patients with actinic keratosis on the face and scalp.
Slovenian: Zdravilo Zyclara se je izkazalo za učinkovito pri odstranjevanju aktiničnih keratoz s kože v dveh glavnih študijah, ki sta vključevali 479 bolnikov z aktinično keratozo na obrazu in lasišču.
English: The patient's response to treatment should be evaluated 8 weeks after the end of treatment, and a third 2-week course may be considered if needed.
Slovenian: Bolnikov odziv na zdravljenje je treba oceniti osem tednov po koncu zdravljenja, po tem pa se presodi, ali je potrebno tretje dvotedensko zdravljenje.
English: Zyclara is used to treat adults whose immune system (the body's natural defences) is working normally when other skin treatments for actinic keratosis cannot be used or are less appropriate.
Slovenian: Zdravilo Zyclara se uporablja za zdravljenje odraslih, pri katerih imunski sistem (naravni obrambni mehanizem telesa) deluje normalno in kadar drugačno zdravljenje aktiničnih keratoz ni mogoče ali je manj primerno.
English: Why is Zyclara approved?
Slovenian: Zakaj je bilo zdravilo Zyclara odobreno?
English: The reference medicine for Zyclara is Aldara, which contains imiquimod at 5% strength.
Slovenian: Referenčno zdravilo za zdravilo Zyclara je zdravilo Aldara, ki vsebuje imikvimod z jakostjo 5 %.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zyclara have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Zyclara upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: The cream should remain on the skin overnight (for about 8 hours) before being washed off. Daily treatment should continue for 2 weeks.
Slovenian: Krema mora ostati na koži čez noč (približno osem ur), preden se spere.
English: It contains the active substance imiquimod at 3.75% strength (100 mg cream contains 3.75 mg imiquimod).
Slovenian: Zdravilo vsebuje zdravilno učinkovino imikvimod z jakostjo 3,75 % (100 mg kreme vsebuje 3,75 mg imikvimoda).
English: It is not intended to provide practical advice on how to use Zyclara.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: What are the risks associated with Zyclara?
Slovenian: Kakšna tveganja so povezana z zdravilom Zyclara?
English: One or two sachets of Zyclara are applied in a thin layer to the affected areas of the face or balding scalp once a day before bedtime.
Slovenian: Ena ali dve vrečici zdravila Zyclara se naneseta v tanki plasti na prizadeto področje na obrazu ali neporaščenih delih lasišča enkrat dnevno pred spanjem.
English: These substances help to kill the abnormal cells in the skin that lead to keratosis.
Slovenian: Te snovi pomagajo uničiti nenormalne celice v koži, ki se lahko razvijejo v keratozo.
English: This means that it uses the immune system to bring about its effect.
Slovenian: To pomeni, da učinek doseže z delovanjem na imunski sistem.
English: The active substance in Zyclara cream, imiquimod, is an immune response modifier.
Slovenian: Zdravilna učinkovina v zdravilu Zyclara krema, imikvimod, je modifikator imunskega odziva.
English: About 11% of patients in studies with Zyclara required treatment to be interrupted due to this kind of side effect on the skin.
Slovenian: Približno 11 % bolnikov, ki so sodelovali v študijah z zdravilom Zyclara, se je moralo zaradi teh neželenih učinkov na koži prenehati zdraviti.
English: For more information about treatment with Zyclara, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Zyclara preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: Treatment with Zyclara has the advantage of being easier to adhere to than Aldara treatment because it has a simpler dosing regimen.
Slovenian: Prednost uporabe zdravila Zyclara je v tem, da je lažje upoštevati režim zdravljenja kot pri zdravilu Aldara, saj je način odmerjanja preprostejši.
English: For practical information about using Zyclara, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Zyclara naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: Zyclara is available as a 3.75% cream in individual sachets.
Slovenian: Zdravilo Zyclara je na voljo v obliki kreme z jakostjo 3,75 % v posamičnih vrečicah.
English: Two doses of Zyclara (2.5% and 3.75%) were compared with placebo (a dummy treatment) in these studies, and the main measure of effectiveness was the number of patients whose skin was completely cleared of the actinic keratosis after treatment.
Slovenian: V teh študijah so dva odmerka zdravila Zyclara (2,5 % in 3,75 %) primerjali s placebom (zdravilom brez zdravilne učinkovine), pri čemer je bilo glavno merilo učinkovitosti število bolnikov, pri katerih so bile aktinične keratoze po zdravljenju popolnoma odstranjene.
English: Most patients using Zyclara experience side effects on the skin where the medicine was applied (most commonly redness, scab formation, dryness and shedding of the skin).
Slovenian: Večina bolnikov, ki so uporabljali zdravilo Zyclara, je imela neželene učinke na koži na mestu nanosa zdravila (najpogosteje pordelost kože, nastanek krast, suha koža in luščenje kože).
English: Zyclara at a lower strength (2.5%) had a lower clearance rate than the 3.75% strength.
Slovenian: Pri uporabi zdravila Zyclara z manjšo jakostjo (2,5 %) je bila stopnja odstranitve nižja kot pri 3,75-odstotni jakosti.
English: How does Zyclara work?
Slovenian: Kako zdravilo Zyclara deluje?
English: Zyclara is a cream used to treat actinic keratosis on the face and balding parts of the scalp.
Slovenian: Zdravilo Zyclara je krema, ki se uporablja za zdravljenje aktiničnih keratoz na obrazu in neporaščenih delih lasišča.
English: For the full list of side effects and restrictions with Zyclara, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Zyclara glejte navodilo za uporabo.
English: Around 36% of patients treated with Zyclara 3.75% cream in the two studies had complete clearance compared with around 6% of patients treated with placebo.
Slovenian: Stopnja popolne odstranitve je bila okoli 36 % pri bolnikih, ki so se zdravili z zdravilom Zyclara 3,75 % v obliki kreme, v primerjavi s približno 6 % pri bolnikih, ki so prejemali placebo.
English: How is Zyclara used?
Slovenian: Kako se zdravilo Zyclara uporablja?
English: These could be signs of a severe allergic reaction
Slovenian: To so lahko znaki hude alergijske reakcije.
English: • think you may be pregnant
Slovenian: • mislite, da bi lahko bili noseči
English: Millmount Healthcare Limited Block 7, City North Business Campus, Stamullen Co. Meath, K32 YD60 Ireland
Slovenian: Millmount Healthcare Limited Block 7, City North Business Campus, Stamullen Co. Meath, K32 YD60 Irska
English: The protein part is very similar to a natural protein produced by your own body.
Slovenian: Beljakovinski del je zelo podoben naravni beljakovini, ki nastaja v telesu.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/18/1303/001
Slovenian: ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/18/1303/001
English: OTHER SPECIAL WARNING(S), IF NECESSARY Avoid vigorous shaking.
Slovenian: DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Izogibajte se močnemu stresanju.
English: Your doctor will tell you what you can take to ease the bone pain
Slovenian: Zdravnik vam bo povedal, kaj lahko vzamete za lajšanje bolečin v kosteh.
English: The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines webportal.
Slovenian: Zahteve glede predložitve posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in na vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
English: • It is important that you read the instructions before using the syringe so you understand how to administer the injection.
Slovenian: • Pomembno je, da preberete navodila pred uporabo injekcijske brizge , da boste razumeli, kako dati zdravilo.
English: • are pregnant
Slovenian: • ste noseči
English: 8 Position fingers.
Slovenian: 8 Postavitev prstov
English: 1 See section “Description of selected adverse reactions” below.
Slovenian: 1 Glejte poglavje „Opis izbranih neželenih učinkov“ spodaj.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 21 September 2018
Slovenian: Datum prve odobritve: 21. septembra 2018
English: OTHER ERA, GmbH - Germany
Slovenian: DRUGI PODATKI ERA, GmbH - Nemčija
English: 29664 Walsrode Germany
Slovenian: 29664 Walsrode Nemčija
English: The recommended injection sites for a subcutaneous injection are the:
Slovenian: Najprimernejša mesta za subkutano injiciranje so:
English: Aortitis [rare frequency] (see section 4.4).
Slovenian: Aortitis [redko] (glejte poglavje 4.4)
English: Your doctor may decide that it would be more convenient for you to inject UDENYCA yourself.
Slovenian: Mogoče se bo zdravnik odločil, da bi bilo za vas prikladneje, če si zdravilo UDENYCA injicirate sami.
English: UDENYCA is for use in adults aged 18 and over.
Slovenian: Zdravilo UDENYCA je namenjeno uporabi pri odraslih, starih 18 ali več let.
English: This section contains information on how to give yourself an injection of UDENYCA.
Slovenian: To poglavje vsebuje informacije o tem, kako si sami injicirate zdravilo UDENYCA.
English: Limited data indicate that the pharmacokinetics of pegfilgrastim in elderly subjects (> 65 years) is similar to that in adults.
Slovenian: Omejeni podatki kažejo, da je farmakokinetika pegfilgrastima pri starejših bolnikih (> 65 let) podobna kot pri odraslih.
English: DO NOT attempt to warm up the syringe in any other way, such as a microwave, hot water, or direct sunlight.
Slovenian: Injekcijske brizge NIKAKOR NE grejte na kateri koli drugi način, kot na primer v mikrovalovni pečici, vroči vodi ali na soncu.
English: In order to improve the traceability of biological medicinal products, the trade name of the administered product should be clearly recorded.
Slovenian: Za izboljšanje sledljivosti bioloških zdravil je treba v bolnikovi dokumentaciji jasno zabeležiti zaščiteno ime uporabljenega zdravila.
English: The adverse reactions are ranked under heading of frequency using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (1/1,000 to <1/100), rare (1/10,000 to <1/1,000), very rare (<1/10,000) and not known (cannot be estimated from the available data).
Slovenian: Neželeni učinki so razdeljeni po pogostnosti in sicer: zelo pogosti ((≥ 1/10), pogosti (≥1/100 to <1/10), občasni (1/1,000 to <1/100), redki (1/10,000 to <1/1,000), zelo redki (<1/10,000) in brez podatkov (ni mogoče oceniti na podlagi znanih podatkov).
English: Do not use this medicine after the expiry date, which is stated on the carton and on the syringe label after EXP.
Slovenian: Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in na nalepki injekcijske brizge poleg oznake »EXP«.
English: The concentration is 10 mg/ml based on protein content only**.
Slovenian: Koncentracija je 10 mg/ml na podlagi količine beljakovine same **.
English: INFORMATION IN BRAILLE UDENYCA
Slovenian: PODATKI V BRAILLOVI PISAVI UDENYCA
English: UDENYCA has not been tested in pregnant women.
Slovenian: Zdravila UDENYCA pri nosečnicah niso preskusili.
English: Your doctor has given you UDENYCA to encourage your bone marrow (part of the bone which makes blood cells) to produce more white blood cells that help your body fight infection.
Slovenian: Vaš zdravnik vam je predpisal zdravilo UDENYCA, da bi spodbudilo vaš kostni mozeg (tisti del kosti, ki izdeluje krvničke) k izdelavi več belih krvničk, ki pomagajo vašemu telesu boriti se proti okužbam.
English: A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from UDENYCA therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Slovenian: Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom UDENYCA, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
English: The most frequently reported adverse reactions were bone pain (very common) and musculoskeletal pain (common).
Slovenian: Neželena učinka, o katerih so najpogosteje poročali, sta bila bolečina v kosteh (zelo pogosto) in kostno-mišična bolečina (pogosto).
English: What you need to know before you use UDENYCA Do not use UDENYCA - if you are allergic to pegfilgrastim, filgrastim, or any of the other ingredients of this medicine.
Slovenian: Kaj morate vedeti, preden boste uporabili zdravilo UDENYCA Ne uporabljajte zdravila UDENYCA če ste alergični na pegfilgrastim, filgrastim, ali katero koli sestavino tega zdravila.
English: Tel: +49 (0) 5161 9890 0
Slovenian: Tel: +49 (0) 5161 9890 0 Faks: +49 (0) 5161 9890 18
English: If frozen, thaw in the refrigerator before administration.
Slovenian: Če jo zamrznete, jo odtajajte v hladilniku pred injiciranjem.
English: Other medicines and UDENYCA
Slovenian: Druga zdravila in zdravilo UDENYCA
English: • Inflammation of the aorta (the large blood vessel which transports blood from the heart to the body), see section 2
Slovenian: • vnetje aorte (velike žile, ki prenaša kri iz srca po telesu), glejte poglavje 2.
English: Aortitis has been reported after G-CSF administration in healthy subjects and in cancer patients.
Slovenian: Po uporabi G-CSF so poročali o aortitisu pri zdravih subjektih in bolnikih z rakom.
English: A: Wash your hands with soap and warm water (see Figure 5).
Slovenian: A: Umijte roke z milom in toplo vodo (glejte sliko 5).
English: However, the long-term effects of pegfilgrastim have not been established in acute myeloid leukaemia; therefore, it should be used with caution in this patient population.
Slovenian: Vendar dolgoročni učinki pegfilgrastima pri akutni mieloični levkemiji niso ugotovljeni, zato ga je treba pri tej populaciji bolnikov uporabljati previdno.
English: If your doctor has told you that you (or your child) have an intolerance to some sugars or if you have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in which a person cannot break down fructose, talk to your doctor before you (or your child) take or receive this medicine.
Slovenian: Če vam je zdravnik povedal, da imate vi (ali vaš otrok) prirojeno motnjo intolerance za fruktozo, redko prirojeno bolezen zaradi katere oseba ne more prebavljati fruktoze, se posvetujte z zdravnikom, preden začnete jemati to zdravilo (ali preden ga vaš otrok začne prejemati)..
English: DO NOT inject into moles, scars, birthmarks, or areas where the skin is tender, bruised, red, or hard.
Slovenian: NE INJICIRAJTE v kožna znamenja, brazgotine, rojstna znamenja ali na področjih, kjer je koža mehka, poškodovana, rdeča ali trda.
English: Do not shake UDENYCA vigorously as this may affect its activity.
Slovenian: Zdravila UDENYCA ne smete močno stresati, saj lahko to vpliva na njegovo delovanje.
English: 3 Wash your hands and remove syringe from tray.
Slovenian: 3 Umijte roke in odstranite injekcijsko brizgo iz pladnja.
English: Specific interaction or metabolism studies have not been performed, however, clinical trials have not indicated an interaction of pegfilgrastim with any other medicinal products.
Slovenian: Posebnih študij medsebojnega delovanja ali presnove niso izvedli, vendar klinična preskušanja niso pokazala medsebojnega delovanja pegfilgrastim a s kakšnimi drugimi zdravili.
English: • This medicine comes as a one-time use pre-filled safety syringe that contains a single dose.
Slovenian: • To zdravilo je na voljo v obliki napolnjene varnostne injekcijske brizge za enkratno uporabo, ki vsebuje en odmerek.
English: Your doctor may monitor your condition more closely
Slovenian: Zdravnik bo lahko natančneje kontroliral vaše stanje.
English: When left at room temperature for more than 72 hours it should be discarded.
Slovenian: Če je bilo na sobni temperaturi več kot 72 ur, ga je treba zavreči.
English: A: Place the sealed syringe tray on a flat, clean surface and allow it to sit at room temperature for at least 30 minutes (see Figure 3).
Slovenian: A: Zapečaten pladenj z injekcijsko brizgo postavite na čisto, ravno površino in jo pustite na sobni temperaturi vsaj 30 minut (glejte sliko 3).
English: What UDENYCA is and what it is used for
Slovenian: Kaj je zdravilo UDENYCA in za kaj ga uporabljamo
English: B: Gather the following supplies (see Figure 4).
Slovenian: B: Pripravite naslednje pripomočke (glejte sliko 4).
English: UDENYCA may be used if it is accidentally frozen for a single period of less than 24 hours.
Slovenian: Zdravila UDENYCA smete uporabiti, če je bilo pomotoma zamrznjeno eno samo obdobje, krajše od 24 ur.
English: 5 Select the injection site.
Slovenian: 5 Izberite mesto injiciranja.
English: polysorbate 20 and water for injections.
Slovenian: 20 in voda za injekcije.
English: FIGURE 17 DO NOT throw away loose needles and syringes in your household waste.
Slovenian: SLIKA 17 NE ODVRZITE posameznih igel ali injekcijskih brizg v vaše hišne smeti.
English: If you develop or are likely to develop cancers of the blood, you should not use UDENYCA, unless instructed by your doctor.
Slovenian: Če se vam bodo pojavili ali je verjetno, da se vam bodo pojavili krvni raki, ne smete uporabljati zdravila UDENYCA, razen če vam to naroči zdravnik.
English: If leukocyte counts exceed 50 x 109/l after the expected nadir, this medicine should be discontinued immediately.
Slovenian: Če število levkocitov po pričakovanem najmanjšem številu preseže 50 x 109/l, je treba nemudoma prenehati z zdravljenjem s tem zdravilom.